CClinicalTrials.gg
RecruitingNCT05683041PALLMUpdated Aug 20, 2026

Prevention of Intra-uterine Adhesions Following Laparoscopic and Laparotomic Myomectomy

An interventional study of Hyalobarrier in Myoma, sponsored by University Hospital, Ghent. Recruiting at 1 site in Belgium. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by University Hospital, Ghent · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

Clinical study on the prevention of intrauterine adhesions after laparoscopic or laparotomic myomectomy.

Myomas are common in women of reproductive age and myomectomy can lead to intra-uterine adhesions, which can be detrimental to fertility. This study investigates whether the use of an intrauterine gel can prevent the development of these adhesions.

Read the detailed description

Design:

Double-blind, randomized controlled pilot trial.

Participant:

  • age between 18 and 45 years.
  • intramurale and/or subserosal myoma (FIGO 3-6), and/or hybrid myoma (with a connection to the endometrium and serosa (FIGO 2-5), who are scheduled for laparoscopic / laparotomic myomectomy.
  • absence of intra-uterine adhesions on preoperative diagnostic hysteroscopy

Treatment:

Application of intrauterine Hyalobarrier® gel endo at time of surgery

Control:

No application of Hyalobarrier® gel endo

Follow up:

Second-look hysteroscopy after 3months

To blind all trial participants and gynaecologists doing second-look hysteroscopy, 10 ml of a sterile ultrasound gel will be applied into the vagina at the end of the procedure in all women regardless of their treatment allocation.

02

Conditions studied

  • Myoma

Browse trials for

Keywords

  • Postoperative adhesions
  • Intrauterine adhesions
  • Myomectomy
  • Laparoscopic myomectomy
  • Laparotomic myomectomy
  • Adhesion prevention
  • Antiadhesion method
03

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • age between 18 and 45 years.
  • intramurale and/or subserosal myoma (FIGO 3-6), and/or hybrid myoma (with a connection to the endometrium and serosa (FIGO 2-5), who are scheduled for laparoscopic / laparotomic myomectomy.
  • absence of intra-uterine adhesions on preoperative diagnostic hysteroscopy

Exclusion criteria

Exclusion Criteria:

  • pregnancy.
  • laparoscopic or laparotomic myomectomy in combination with an operative hysteroscopy.
  • presence of endometritis.
  • other antiadhesion methods
04

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    intrauterine gel application

    Application of Hyalobarrier intrauterine after myomectomy.

    Device: Hyalobarrier

  • No intervention
    no intra-uterine gel application

    No application of Halobarrier intrauterine after myomectomy.

Interventions

  • DeviceHyalobarrier

    Hyalobarrier is a viscous, transparent gel and is used as a preventive measure for post-operative adhesions in the abdominal and uterine cavity.

    Also known as: anti-adhesive gel

05

What researchers measure

Primary outcomes

  1. Adhesion formation postoperatief.

    The presence of intra-uterine adhesions on a second look hysteroscopy.

    Time frame: 3 months post surgery

Secondary outcomes

  1. Severity of adhesion formation

    American Fertility Society classification (AFS) and classification of Valle and Sciarra are used to describe the severity.

    Time frame: 3 months post surgery, at the time of the hysteroscopy.

06

Study locations

1 of 1 sites recruiting
  • University Hospital Ghent
    Ghent, Belgium
    • Steffi van Wessel, Dr. · Contact · 093320758
    • Steven Weyers, Prof. Dr. · Contact · 093320758
    • Steffi van Wessel · Principal investigator
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT05683041
Lead sponsor
University Hospital, Ghent
Collaborators
Nordic Pharma SAS
Responsible party
Sponsor
First posted
Jan 12, 2023
Start date
Feb 22, 2023
Primary completion
Jan 2029 (estimated)
Completion
Jan 2030 (estimated)
Last update
Aug 20, 2026

Study contacts

Steffi Van Wessel, Dr.
Contact
studieco.vrouwenkliniek@uzgent.be
093320758
Steven Weyers, Prof. dr.
Contact
studieco.vrouwenkliniek@uzgent.be
093320758

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion